Design, synthesis, and antitumor efficacy of novel 5-deazaflavin derivatives backed by kinase screening, docking, and ADME studies

References

• Shrestha AR, Ali HI, Ashida N, Nagamatsu T. Antitumor studies. Part 5: synthesis, antitumor activity, and molecular docking study of 5-(monosubstituted amino)-2-deoxo-2-phenyl-5-deazaflavins. Bioorg Med Chem. 2008;16(20):9161–9170.
   PubMed Web of Science ®Google Scholar
• Ali HI, Tomita K, Akaho E, Kambara H, Miura S, Hayakawa H, Ashida N, Kawashima Y, Yamagishi T, Ikeya H, et al. Antitumor studies. Part 1: design, synthesis, antitumor activity, and AutoDock study of 2-deoxo-2-phenyl-5-deazaflavins and 2-deoxo-2-phenylflavin-5-oxides as a new class of antitumor agents. Bioorg Med Chem. 2007;15(1):242–256.
   PubMed Web of Science ®Google Scholar
• Ali HI, Ashida N, Nagamatsu T. Antitumor studies. part 3: design, synthesis, antitumor activity, and molecular docking study of novel 2-methylthio-, 2-amino-, and 2-(N-substituted amino)-10-alkyl-2-deoxo-5-deazaflavins. Bioorg Med Chem. 2007;15(19):6336–6352.
   PubMed Web of Science ®Google Scholar
• Ali HI, Ashida N, Nagamatsu T. Antitumor studies. Part 4: Design, synthesis, antitumor activity, and molecular docking study of novel 2-substituted 2-deoxoflavin-5-oxides, 2-deoxoalloxazine-5-oxides, and their 5-deaza analogs. Bioorg Med Chem. 2008;16(2):922–940.
   PubMed Web of Science ®Google Scholar
• Ali HI, Tomita K, Akaho E, Kunishima M, Kawashima Y, Yamagishi T, Ikeya H, Nagamatsu T. Antitumor studies – part 2: structure-activity relationship study for flavin analogs including investigations on their in vitro antitumor assay and docking simulation into protein tyrosine kinase. Eur J Med Chem. 2008;43(7):1376–1389.
   PubMed Web of Science ®Google Scholar
• Ali HI, Nagamatsu T, Akaho E. Structure-based drug design and AutoDock study of potential protein tyrosine kinase inhibitors. Bioinformation. 2011;5(9):368–374.
   PubMedGoogle Scholar
• Malki WH, Gouda AM, Ali HEA, Al-Rousan R, Samaha D, Abdalla AN, Bustamante J, Abd Elmageed ZY, Ali HI. Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition. Eur J Med Chem. 2018;152:31–52.
   PubMed Web of Science ®Google Scholar
• Wilson JM, Henderson G, Black F, Sutherland A, Ludwig RL, Vousden KH, Robins DJ. Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells. Bioorg Med Chem. 2007;15(1):77–86.
   PubMed Web of Science ®Google Scholar
• Dickens MP, Roxburgh P, Hock A, Mezna M, Kellam B, Vousden KH, Fischer PM. 5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2. Bioorg Med Chem. 2013;21(22):6868–6877.
   PubMed Web of Science ®Google Scholar
• Fenner H, Grauert R, Hemmerich P, Michel H, Massey V. 5-Thia-5-deazaflavin, a 1e–transferring flavin analog. Eur J Biochem. 1979;95(1):183–191.
   PubMedGoogle Scholar
• Kimachi T, Yoneda F, Sasaki T. New synthesis of 5-amino-5-deazaflavin derivatives by direct coupling of 5-deazaflavins and amines. J Heterocycl Chem. 1992;29(4):763–765.
   Web of Science ®Google Scholar
• Yoneda F, Sakuma Y, Hemmerich P. Dehydrogenation of alcohols by pyrimido[4,5-b]quinoline-2(3H),4(10H)-dione (5-deazaflavin). J Chem Soc, Chem Commun. 1977;22(22):825–826.
   Google Scholar
• Eirich LD, Vogels GD, Wolfe RS. Proposed structure for coenzyme F420 from Methanobacterium. Biochemistry. 1978;17(22):4583–4593.
   PubMed Web of Science ®Google Scholar
• Hossain MS, Le CQ, Joseph E, Nguyen TQ, Johnson-Winters K, Foss FW. Jr. Convenient synthesis of deazaflavin cofactor FO and its activity in F(420)-dependent NADP reductase. Org Biomol Chem. 2015;13(18):5082–5085.
   PubMed Web of Science ®Google Scholar
• Philmus B, Decamps L, Berteau O, Begley TP. Biosynthetic versatility and coordinated action of 5'-deoxyadenosyl radicals in deazaflavin biosynthesis. J Am Chem Soc. 2015;137(16):5406–5413.
   PubMed Web of Science ®Google Scholar
• Nagamatsu T,H, Yoneda F. Synthesis of pyridodipyrimidines as a redox catalyst and their autorecycling oxidation of alcohols. J Pharmacobio-Dyn. 1992;15:s-42.
   Google Scholar
• Yoneda F. Organic catalysts and autorecycling reactions. Yakugaku Zasshi. 1984;104(2):97–126.
   PubMed Web of Science ®Google Scholar
• el-Gazzar AB, Hafez HN, Nawwar GA. New acyclic nucleosides analogues as potential analgesic, anti-inflammatory, anti-oxidant and anti-microbial derived from pyrimido[4,5-b]quinolines. Eur J Med Chem. 2009;44(4):1427–1436.
   PubMed Web of Science ®Google Scholar
• El-Gohary NS. Synthesis and in vitro antitumor activity of new quinoline, pyrimido[4,5-b]quinoline, [1,2,3]triazino[4,5-b]quinoline, and [1,2,4]triazolo[2′,3′:3,4]pyrimido[6,5-b]quinoline analogs. Med Chem Res. 2013;22(11):5236–5247.
   Web of Science ®Google Scholar
• Ghorab MM, Ragab FA, Heiba HI, Arafa RK, El-Hossary EM. In vitro anticancer screening and radiosensitizing evaluation of some new quinolines and pyrimido[4,5-b]quinolines bearing a sulfonamide moiety. Eur J Med Chem. 2010;45(9):3677–3684.
   PubMed Web of Science ®Google Scholar
• O'Brien DE, Weinslock LT, Cheng CC. Synthesis of 10-deazariboflavin and related 2,4-dioxopyrimido[4,5-b]quinolones. J Heterocycl Chem. 1970;7(1):99–105.
   Web of Science ®Google Scholar
• Yoneda F, Sakuma Y, Mizumoto S, Ito R. Syntheses of 5-deazaflavines. J Chem Soc Perkin Trans 1. 1976;(16):1805–1805.
   PubMedGoogle Scholar
• Chen X, Tanaka K, Yoneda F. A new synthetic approach to 5-deazaflavin and 5-deaza-10-thiaflavin. Chem Pharm Bull. 1990;38(3):612–615.
   Web of Science ®Google Scholar
• Lacroix A, Fleury J-P. A new synthesis of 5-deazaflavins. Tetrahedron Lett. 1978;19(37):3469–3470.
   Google Scholar
• Marjani AP, Khalafy J, Ebrahimlo ARM, Prager RH. Synthesis of some pyrimido[4,5-b]quinoline derivatives. Bull Korean Chem Soc. 2011;32(7):2183–2186.
   Web of Science ®Google Scholar
• Knabe J, Heckmann R. Dihydroisochinolinumlagerung, 30. Mitt. Synthese einiger Furo[3,2-c]pyridine. Arch Pharm Pharm Med Chem. 1980;313(9):809–811.
   Google Scholar
• Moriyama K, Nagamatsu T, Yoneda F. Synthesis of 8-methylpyrido[2,3-d:6,5-d’X]dipyrimidine-2,4,6(3H,10H,7H)-triones and their use in the oxidation of alcohols. J Heterocycl Chem. 1986;23(1):241–243.
   Web of Science ®Google Scholar
• Taylor EC, Cain CK. Pteridines. VII. The synthesis of 2-alkylaminopteridines. J Am Chem Soc. 1952;74(7):1644–1647.
   Web of Science ®Google Scholar
• Taylor EC, Cain CK. Pteridines. VI. Replacement reactions of amino, hydroxyl, and mercapto groups in the pteridine series. J Am Chem Soc. 1951;73(9):4384–4387.
   Web of Science ®Google Scholar
• Coppola GM, Schuster HF. The chemistry of 2H-3,1-benzoxazine-2,4-(1H)-dione (isatoic anhydride). XXI: [1]. A mild process for the preparation of 10-alkyl-9-acridanones and it’s application to the synthesis of acridone alkaloids. J Heterocycl Chem. 1989;26(4):957–964.
   Web of Science ®Google Scholar
• Kadry AM, Aal EHA, Abdel-Fattah HA, Al-Mahmoudy AM. Synthesis an antimicrobial activity of new triazolopyrimidinecarbonitrile derivatives. Arkivoc. 2008;2008(10):127–134.
   Google Scholar
• Farghaly AH., Abdel-Rahman   Synthesis, reactions and antimicrobial activity of some new indolyl-1,3,4-oxadiazole, triazole and pyrazolederivatives. Jnl Chinese Chemical Soc. 2004;51(1):147–156.
   Web of Science ®Google Scholar
• Irfan MS. S. Synthesis, characterization and antimicrobial activity of some substituted Ǹ-arylidene-2-(quinolin-8-yloxy)acetohydrazide. Acta Pharm Sci. 2009;51:163–168.
   Google Scholar
• Bhat I, Chaithanya S, Satyanarayana PD, Kalluraya B. The synthesis and antimicrobial study of some azetidinone derivatives with the para-anisidine moiety. J Serb Chem Soc. 2007;72(5):437–442.
   Web of Science ®Google Scholar
• Cacic M, Trkovnik M, Cacic F, Has-Schon E. Synthesis and antimicrobial activity of some derivatives of (7-hydroxy-2-oxo-2H-chromen-4-yl)-acetic acid hydrazide. Molecules. 2006;11(2):134–147.
   PubMed Web of Science ®Google Scholar
• Dabholkar V,SASA. Synthesis of novel oxazoles and their hydrazones. Rasayan J Chem. 2010;3:761–765.
   Google Scholar
• Nogimori T, Emerson CH, Braverman LE, Wu CF, Gambino J, Wright GE. Synthesis of 6-anilino-2-thiouracils and their inhibition of human placenta iodothyronine deiodinase. J Med Chem. 1985;28(11):1692–1694.
   PubMed Web of Science ®Google Scholar
• Hübsch W, Pfleiderer W. Part LXXXVII. Synthesis and properties of 8-substituted 2-Thiolumazines. HCA. 1988;71(6):1379–1391.
   Web of Science ®Google Scholar
• Fathalla W, Čajan M, Pazdera P. Regioselectivity of electrophilic attack on 4-methyl-1-thioxo-1,2,4,5-tetrahydro[1,2,4]triazolo[4,3-a]quinazolin-5-one. Part 1: reactions at the sulfur atom. Molecules. 2001;6(6):557–573.
   Web of Science ®Google Scholar
• Israel M, Protopapa HK, Schlein HN, Modest EJ. Pyrimidine derivatives. v. synthesis of substituted pyrimidines from 4-amino-6-chloro-2-methylthiopyrimidine. J Med Chem. 1964;7:5–10.
   PubMed Web of Science ®Google Scholar
• Soule HD, Maloney TM, Wolman SR, Peterson WD, Jr., Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990;50(18):6075–6086.
   PubMed Web of Science ®Google Scholar
• Masters JR. HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer. 2002;2(4):315–319.
   PubMed Web of Science ®Google Scholar
• Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13(4):215–20110812.
   PubMed Web of Science ®Google Scholar
• Singh JK, Simões BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013;15(4):210.
   PubMed Web of Science ®Google Scholar
• Abdel-Fatah TM, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, et al. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Mol Oncol. 2015;9(3):569–585.
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J. 2000;19(13):3159–3167.
   PubMed Web of Science ®Google Scholar
• Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA. 2011;108(46):18708–18713.
   PubMed Web of Science ®Google Scholar
• Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villén J, Li J, Cohn MA, Cantley LC, Gygi SP. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA. 2004;101(33):12130–12135.
   PubMed Web of Science ®Google Scholar
• Watson NA, Cartwright TN, Lawless C, Cámara-Donoso M, Sen O, Sako K, Hirota T, Kimura H, Higgins JMG. Kinase inhibition profiles as a tool to identify kinases for specific phosphorylation sites. Nat Commun. 2020;11(1):1684–20200403.
   PubMed Web of Science ®Google Scholar
• Wu C, Macleod I, Su AI. BioGPS and MyGene.info: organizing online, gene-centric information. Nucleic Acids Res. 2013;41(Database issue):D561–5.
   PubMed Web of Science ®Google Scholar
• Grueneberg DA, Degot S, Pearlberg J, Li W, Davies JE, Baldwin A, Endege W, Doench J, Sawyer J, Hu Y, et al. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc Natl Acad Sci USA. 2008;105(43):16472–16477.
   PubMed Web of Science ®Google Scholar
• Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973;51(5):1409–1416.
   PubMed Web of Science ®Google Scholar
• Landry JJ, Pyl PT, Rausch T, Zichner T, Tekkedil MM, Stütz AM, Jauch A, Aiyar RS, Pau G, Delhomme N, et al. The genomic and transcriptomic landscape of a HeLa cell line. G3. 2013;3(8):1213–1224.
   Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–643.
   PubMed Web of Science ®Google Scholar
• Shajahan-Haq AN, Cook KL, Schwartz-Roberts JL, Eltayeb AE, Demas DM, Warri AM, Facey CO, Hilakivi-Clarke LA, Clarke R. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol Cancer. 2014;13:239–20141023.
   PubMed Web of Science ®Google Scholar
• Hafner M, Niepel M, Chung M, Sorger PK. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods. 2016;13(6):521–527.
   PubMed Web of Science ®Google Scholar
• Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol. 2012;920:613–626.
   PubMedGoogle Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.
   PubMed Web of Science ®Google Scholar
• Green DR. The death receptor pathway of apoptosis. Cold Spring Harb Perspect Biol. 2022;14(2):a041053.
   PubMed Web of Science ®Google Scholar
• Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 2007;8(9):741–752.
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, Rheinberger P, Centeleghe M, Fabbro D, Manley PW. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr. 2007;63(Pt 1):80–93.
   PubMedGoogle Scholar
• Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, et al. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell. 2016;30(3):485–498.
   PubMed Web of Science ®Google Scholar
• Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 2004;279(30):31655–31663.
   PubMed Web of Science ®Google Scholar
• George DM, Breinlinger EC, Friedman M, Zhang Y, Wang J, Argiriadi M, Bansal-Pakala P, Barth M, Duignan DB, Honore P, et al. Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit. J Med Chem. 2015;58(1):222–236.
   PubMed Web of Science ®Google Scholar
• Tresaugues L, Roos A, Arrowsmith CH, Berglund H, Bountra C, Collins R, Edwards AM, Flodin S, Flores A, Graslund S, et al. Crystal structure of VEGFR1 in complex with N-(4-chlorophenyl)-2-((pyridin-4-ylmethyl)amino)benzamide. (To Be Published). https://www.rcsb.org/structure/3HNG.
   Google Scholar
• Levinson NM, Boxer SG. A conserved water-mediated hydrogen bond network defines bosutinib’s kinase selectivity. Nat Chem Biol. 2014;10(2):127–132.
   PubMed Web of Science ®Google Scholar
• Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257–W263.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717–20170303.
   PubMed Web of Science ®Google Scholar
• Nagamatsu T, Hashiguchi Y, Yoneda F. A new, general, and convenient synthesis of 5-deazaflavins (5-deazaisoalloxazines) and bis-(5-deazaflavin-10-yl) alkanes. J Chem Soc Perkin Trans 1. 1984;1:561–565.
   Google Scholar
• Miura S, Yoshimura Y, Endo M, Machida H, Matsuda A, Tanaka M, Sasaki T. Antitumor activity of a novel orally effective nucleoside, 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine. Cancer Lett. 1998;129(1):103–110.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Mahmoud S, Samaha D, Mohamed MS, Abou Taleb NA, Elsawy MA, Nagamatsu T, Ali HI. Design, synthesis, antitumor activity and molecular docking study of novel 5-deazaalloxazine analogs. Molecules. 2020;25(11):2518.
   PubMed Web of Science ®Google Scholar
• Elwaie TA, Abbas SE, Aly EI, George RF, Ali H, Kraiouchkine N, Abdelwahed KS, Fandy TE, El Sayed KA, Abd Elmageed ZY, et al. HER2 kinase-targeted breast cancer therapy: design, synthesis, and in vitro and in vivo evaluation of novel lapatinib congeners as selective and potent her2 inhibitors with favorable metabolic stability. J Med Chem. 2020;63(24):15906–15945.
   PubMed Web of Science ®Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184(1):39–51.
   PubMed Web of Science ®Google Scholar
• Sineh Sepehr K, Baradaran B, Mazandarani M, Yousefi B, Abdollahpour Alitappeh M, Khori V. Growth-inhibitory and apoptosis-inducing effects of Punica granatum L. var. spinosa (Apple Punice) on fibrosarcoma cell lines. Adv Pharm Bull. 2014;4(Suppl 2):583–590.
   PubMedGoogle Scholar
• Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–2791.
   PubMed Web of Science ®Google Scholar